Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

- Neumifil is a novel broad-spectrum anti-viral product that was shown to be well-tolerated with no safety signals at all doses tested - Pneumagen plans to conduct a Phase 2 Influenza challenge

Related Keywords

United Kingdom ,Scotland ,Frazer Hall ,Prnewswire Pneumagen ,Kostenloser Wertpapierhandel ,Geoff Kitson ,Douglas Thomson ,Evelyn Mccormack ,Sandi Greenwood ,University Of St Andrews ,Chief Medical Officer ,Respiratory Syncytial Virus ,David Dible ,Carbohydrate Binding Molecule ,Influenza Virus ,Pneumagen ,Nnounces ,Positive ,Line ,Results ,Rom ,Hase ,Study ,Valuating ,Eumifil ,Product ,Esigned ,Prevention ,Treatment ,Viral ,Espiratory ,Tract ,Infections ,